Journal of Rehabilitation Research & Development (JRRD)

Quick Links

  • Health Programs
  • Protect your health
  • Learn more: A-Z Health
Veterans Crisis Line Badge
 

JRRD at a Glance


Validation of erythropoietin use data on Medicare's End-Stage Renal Disease Medical Evidence Report

Michael J. Fischer, MD, MSPH, et al.

Veterans are at high risk for developing kidney disease, and those who develop the disease have extremely high morbidity and mortality rates. Anemia is a frequent complication of kidney disease and leads to poor health. To treat anemia successfully in veterans, physicians administer erythropoiesis-stimulating agents (ESAs). Much of the prior research investigating the relationship between ESAs, anemia, and kidney disease is based on information from Medicare's Medical Evidence Report (Form 2728). Before this study, the accuracy of the information on Form 2728 was not known. This study found significant errors in ESA information reported on Form 2728, which could have led to biased findings and misunderstandings in prior research. Recognition of these shortcomings of Form 2728 will benefit researchers because they will be able to conduct better studies of this matter in the future.

Volume 47 Number 8, 2010
   Pages 751 — 762


This article and any supplementary material should be cited as follows:
Fischer MJ, Stroupe KT, Hynes DM, Blemur P, Sohn M-W, Browning MM, Huo Z, O'Hare AM, Kaufman JS. Validation of erythropoietin use data on Medicare's End-Stage Renal Disease Medical Evidence Report. J Rehabil Res Dev. 2010;47(8):751-62.
DOI:10.1682/JRRD.2009.08.0108
CrossRef

View HTML  ¦  View PDF  ¦  Contents Vol. 47, No. 8

Last Reviewed or Updated  Wednesday, October 27, 2010 10:02 AM